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Pathogenic variants of the huntingtin (HTT) protein and their aggregation have been investigated in great detail in
brains of Huntington’s disease patients and HTT-transgenic animals. However, little is known about the
physiological brain region- and cell type-specific HTT expression pattern in wild type mice and a potential
recruitment of endogenous HTT to other pathogenic protein aggregates such as amyloid plaques in cross seeding
events. Employing a monoclonal anti-HTT antibody directed against the HTT mid-region and using brain tissue of
three different mouse strains, we detected prominent immunoreactivity in a number of brain areas, particularly in
cholinergic cranial nerve nuclei, while ubiquitous neuronal staining appeared faint. The region-specific distribution
of endogenous HTT was found to be comparable in wild type rat and hamster brain. In human amyloid precursor
protein transgenic Tg2576 mice with amyloid plaque pathology, similar neuronal HTT expression patterns and a
distinct association of HTT with Abeta plaques were revealed by immunohistochemical double labelling.
Additionally, the localization of HTT in reactive astrocytes was demonstrated for the first time in a transgenic
Alzheimer’s disease animal model. Both, plaque association of HTT and occurrence in astrocytes appeared to be
age-dependent. Astrocytic HTT gene and protein expression was confirmed in primary cultures by RT-qPCR and by
immunocytochemistry. We provide the first detailed analysis of physiological HTT expression in rodent brain and,
under pathological conditions, demonstrate HTT aggregation in proximity to Abeta plaques and Abeta-induced
astrocytic expression of endogenous HTT in Tg2576 mice.
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Huntingtin (HTT) is a 348 kDa protein mainly known for
its pathological role in Huntington’s disease (HD). Under-
lying the autosomal dominantly inherited HD is a patho-
logical increase of CAG repeats in the HTT gene exon 1
that leads to a polyglutamine (polyQ) expansion with n > 39
in the corresponding protein [47]. Additionally, the protein
contains several cleavage sites for caspases and calpains© The Author(s). 2019 Open Access This artic
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gested to play a significant role in the pathology. As a result,
the HTT protein undergoes conformational changes and ac-
cumulates in intracellular aggregates [45, 66]. Clinically, the
disease is marked by a progressive loss of motoric and cog-
nitive abilities and the selective death of medium spiny neu-
rons in the striatum with a strong correlation between the
length of polyQ and the age of disease onset [29, 84, 85].
Since the HTT polyQ expansion is decisive for HD devel-
opment, most research so far focused on its pathological
role and only little is known about the physiological func-
tion of HTT [9, 50]. The protein is ubiquitously expressedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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brain [88]. The mouse Htt gene is located on chromosome
5 and shows 86% homology to the human gene and 91%
homology to the protein sequence. The main difference is
reflected by the physiological presence of only six CAG re-
peats in mice in comparison to the mean length of 20–22
CAGs in unaffected human individuals [2]. Systemically,
physiological HTTappears to play a significant role in brain
development during embryogenesis, as knock-out mice die
at an early embryonic stage [19]. Subcellularly, the physio-
logical form of HTT is mainly localized to the cytoplasm,
but some studies report presence of HTT or HTT frag-
ments in the nucleoplasm as well [4, 17, 37, 64, 70]. How-
ever, so far detailed information is neither available on the
physiological region-specific expression pattern of endogen-
ous HTT in mouse brain nor on potential interactions of
HTT with other pathogenic and aggregation-prone proteins
and was therefore investigated in the present study.
Neurodegenerative diseases like HD [45, 66], but also
Alzheimer’s disease (AD) [26] and Parkinson’s disease
(PD) [61] share the characteristics of protein misfolding
followed by aggregation. Traditionally, basic and clinical
research focused on the disease-defining proteins HTT
in HD, Abeta and Tau in AD and α-synuclein in PD, re-
spectively, to reveal underlying mechanism of patho-
genic protein aggregation and its impact on initiation
and progression of disease.
However, post mortem examinations of patients re-
vealed co-existence of different misfolded proteins in
brain tissue, raising the question whether there might be
overlaps and analogies between the specific pathologies
[16, 21, 31, 33]. Given the fact that proteins can act as
homologous seeds [11, 41, 51], the question arose
whether seeding could also take place in a heterologous
manner. For instance, in vitro and in vivo evidence sug-
gests cross talk between the Abeta peptide and prion
protein as well as tau protein [28, 59]. This scenario,
however, is not limited to the co-aggregation of different
peptides affected in a particular disease, but also applies
to co-aggregation of proteins characteristic for different
clinical entities suggesting cross-disease mechanisms of
pathogenic protein co-aggregation events.
In particular, the relationship between aggregating
peptides typical for AD and PD has been studied before.
For example, it was demonstrated that α-synuclein can
initiate tau aggregation [25]. Additionally, the molecular
interrelation of α-synuclein with Abeta was investigated,
demonstrating specific sites of interaction between
membrane-bound α-synuclein with Abeta and vice versa
[52]. In mutant α-synuclein transgenic mice, α-synuclein
overexpression-induced neurodegeneration led to accu-
mulation of insoluble mouse Abeta [23]. Also, in human
PD brain cortical α-synuclein load is associated with
Abeta plaque burden [45]. In a double transgenic mousemodel Abeta was shown to promote α-synuclein aggre-
gation and toxic conversion in vivo, suggesting that ab-
normal interactions between misfolded proteins might
contribute to disease pathogenesis [55]. In the brains of
patients with AD/PD and in transgenic mice, Abeta and
α-synuclein were shown to co-immunoprecipitate and to
form complexes [80]. Additionally, when aspects of AD
and PD pathologies are combined in transgenic mice,
Abeta, tau and α-synuclein pathologies are enhanced
and cognitive decline is accelerated [12].
In contrast, no information is currently available about
the potential cross seeding of Abeta and HTT in AD or
HD-associated conditions. Therefore, in order to study a
potential influence of Abeta pathology on HTT expression
and accumulation we used the transgenic mouse model
Tg2576. These mice overexpress human APP695 with the
Swedish double mutation KM670/671NL and thereby re-
produce the Abeta pathology in an age-dependent manner
starting around 11 to 13months of age [34, 39, 42].
Materials and methods
Animals
The expression of endogenous HTT in brains of
3-month-old wild type animals was analyzed in the inbred
mouse lines C57BL/6N (N = 3) and BALB/c (N = 3) and in
the outbred line CD1 (N = 3) as well as in Wistar rats (N =
3) and hamster (N = 1). In order to reveal a potential influ-
ence of amyloid pathology on endogenous HTT expression
in brain, human APP-transgenic Tg2576 mice and wild type
littermates at postnatal ages of 15, 18, 24, 28 and 32months
were analyzed. Tg2576 mice are on C57BL/6xSJL back-
ground and express human APP695 carrying the Swedish
mutation KM670/671NL driven by the hamster prion pro-
tein promoter [39]. Founder mice were provided by K.
Hsiao-Ashe. Animals were housed at 12 h day/12 h night
cycles with food and water ad libitum in cages that con-
tained red plastic houses (Tecniplast, Hohenpeißenberg,
Germany) and shredded paper flakes to allow nest building.
All experimental protocols were approved by Landesdirek-
tion Sachsen, license numbers T11/16 (rat), T14/16 (ham-
ster) and T28/16 (mouse) and all methods were carried out
in accordance with the relevant guidelines and regulations.
Immunohistochemistry
Tissue preparation
Mice, rats and hamster were sacrificed by CO2 inhalation
and perfused transcardially with 0.9% saline followed by
perfusion with 4% paraformaldehyde in phosphate buffer
(0.1M, pH 7.4). The brains were removed from the skull
and post-fixed by immersion in the same fixative overnight
at 4 °C. After cryoprotection in 30% sucrose in 0.1M phos-
phate buffer for three days, horizontal and coronal sections,
respectively, of 30 μm were cut on a sliding microtome and
collected in phosphate buffer with sodium azide.
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In order to detect HTT, single labelling immunohisto-
chemistry was performed on free floating brain sections
of C57BL/6 N, CD1 and BALB/c mice, Wistar rat and
hamster. To allow for a complete mapping of endogen-
ous HTT expression, series of horizontal sections (one
in eight) and of coronal sections (one in six) were used
for staining. Brain sections were washed in phosphate
buffer for 5 min and endogenous peroxidases were inac-
tivated by treating brain slices with 60% methanol con-
taining 1% H2O2 for 30 min followed by three washing
steps with Tris buffered saline (TBS, 0.1 M, pH 7.4) for
5 min each. After masking unspecific binding sites with
blocking solution (5% normal donkey serum in TBS con-
taining 0.3% Triton X-100) for 30 min sections were in-
cubated with the primary rabbit monoclonal anti-HTT
antibody (EP867Y, raised against HTT amino acids 550–
650; Abcam). In initial experiments brain sections were
incubated with the HTT antibody at dilutions of 1:500,
1:1000, 1:2000 and 1:4000 overnight at 4 °C. Brain sec-
tions were washed three times in TBS for 5 min each be-
fore being incubated with biotinylated, secondary
donkey anti-rabbit antibodies (Dianova; 1:1000) in TBS
containing 2% bovine serum albumin (BSA) for 60 min.
After three washing steps in TBS for 5 min each, slices
were incubated with ExtrAvidin peroxidase (Sigma;
1:2000) in TBS/2% BSA. After washing steps, slices were
pre-incubated in Tris buffer (0.05M, pH 7.6) for 5 min
before visualization of peroxidase binding was per-
formed by incubation with 4 mg 3,3′-diaminobenzidine
(DAB) and 2.5 μl H2O2 per 5ml Tris buffer. After wash-
ing, sections were mounted onto glass slides and cover-
slipped. Based on the results of the different primary
antibody dilutions (Additional file 1: Figure S1a) the re-
spective serial stainings were done with a 1:4000 dilution of
the primary HTT antibody. The specificity of the EP867Y
was validated by the detection of much stronger HTT im-
munoreactivity in brains of HTT transgenic BACHD mice
[30] (Additional file 1: Figure S1b).
Double and triple immunofluorescent labellings
In order to reveal the brain region- and cell type-specific
HTT labelling, the rabbit anti-HTT monoclonal anti-
body was applied in cocktails with primary antibodies
against choline acetyltransferase (ChAT), dopamine and
cAMP regulated phosphoprotein 32 kDa (DARPP-32),
urocortin-1 (Ucn-1), tyrosine hydroxylase (TH), the
astrocyte marker glial fibrillary acidic protein (GFAP)
and the microglial marker ionized calcium-binding
adapter molecule 1 (Iba-1) as specified in Table 1. In
addition, a possible association of HTT with amyloid de-
posits in APP-transgenic Tg2576 mice was investigated
by double labelling of HTT with an antibody directed
against Abeta (4G8) and combined with a fluorescenthistological stain for fibrillary amyloid (Thioflavin S,
ThS), respectively (Table 1). Brain sections were incu-
bated with cocktails of primary antibodies overnight at
4 °C. On the next day, sections were washed three times
with TBS and were then incubated with cocktails of
Cy2-, Cy3- or Cy5-conjugated donkey anti-mouse,
-rabbit or -goat antisera (1:400 each, Dianova) for 60
min at room temperature. After washing, sections were
mounted onto glass slides and coverslipped. ThS stain-
ing was performed on mounted sections, by briefly hy-
drating sections in aqua dest., incubation in ThS (1%)
for 20 min and differentiation in 80% ethanol for 20 to
40min, followed by two rinses in aqua dest., air drying
and coverslipping.
For all single and double immunohistochemical labellings
in brain sections described above and for immunocyto-
chemistry of primary neuronal and glial cell cultures de-
scribed below, control experiments in the absence of
primary antibodies were carried out. In each case, this re-
sulted in unstained brain sections or primary cells, respect-
ively (not shown). In addition, switching the fluorescent
labels of the secondary antibodies (i.e. detection of HTT by
secondary donkey anti-rabbit-Cy3 and visualization of
ChAT by donkey anti-goat-Cy2) generated similar results
to the procedure outlined above (not shown).
Microscopy
Light microscopy
Brain tissue sections of wild type and APP-transgenic
Tg2576 mice immunochemically stained with DAB for
HTT expression were examined with an Axio-Scan.Z1
microscope connected with a Colibri.7 light source and an
Axiocam 506 camera (Carl Zeiss, Göttingen, Germany).
Images of complete brain sections were taken using a 10x
objective lens with 0.45 numerical aperture (Zeiss). The
ThS counterstaining was revealed in the 488 nm fluores-
cence channel of the microscope. Images were digitized
by means of ZEN 2.3 software and exported with the Net-
Scope program (Net-Base Software GmbH, Freiburg,
Germany) where regions of interest were excised.
Confocal laser scanning microscopy
Laser scanning microscopy (LSM 510, Zeiss, Oberko-
chen, Germany) using an Axioplan2 microscope was
performed to reveal co-localization of HTT with the
neuronal markers ChAT, DARPP-32, TH, Ucn-1, with
glial markers GFAP and Iba-1 and with Abeta deposits.
For Cy2-labelled antigens (green fluorescence), an argon
laser with 488 nm excitation was used and emission
from Cy2 was recorded at 510 nm applying a low-range
band pass (505–550 nm). For Cy3-labelled antigens (red
fluorescence), a helium-neon-laser with 543 nm excita-
tion was applied and emission from Cy3 at 570 nm was
detected applying high-range band pass (560–615 nm)
Table 1 Cocktails of antibodies used for double and triple labeling immunohistochemistry
Primary antibody/stain Dilution Host Company Secondary antibody
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy2
ChAT 1:100 goat Millipore donkey anti-goat Cy3
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy2
DARPP-32 1:200 guinea pig Syn. Systems donkey anti-guinea pig Cy3
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy2
Ucn-1 1:100 goat Santa Cruz donkey anti-goat Cy3
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy2
TH 1:50 goat Santa Cruz donkey anti-goat Cy3
HTT (EP867Y) 1:1000 rabbit Abcam biotin-donkey anti-rabbit + SA-HRP
ThS 1% - Sigma -
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy3
Abeta (4G8) 1:2000 mouse Biolegend donkey anti-mouse Cy2
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy3
Iba1 1:200 guinea pig Syn. Systems donkey anti-mouse Cy5
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy3
GFAP (G-A-5) 1:1000 mouse Sigma donkey anti-mouse Cy5
HTT (EP867Y) 1:1000 rabbit Abcam donkey anti-rabbit Cy3
ThS 1% - Sigma -
GFAP (G-A-5) 1:1000 mouse Sigma donkey anti-mouse Cy5
Secondary antibodies were all from Dianova and used at a dilution of 1:400
HTT huntingtin, ChAT choline acetyltransferase, DARPP-32 dopamine and cAMP regulated phosphoprotein 32 kDa, Ucn-1 Urocortin-1, TH tyrosine hydroxylase, SA-
HRP horseradish peroxidase-conjugated streptavidin, Iba1 ionized calcium-binding adapter molecule 1, ThS ThioflavinS, GFAP glial fibrillary acidic protein
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tected using excitation at 650 nm and emission at 670
nm. Images of areas of interest were taken using a 20x
objective lens with 0.75 numerical aperture (Zeiss).
Photoshop CS2 (Adobe Systems, CA) was used to
process the images obtained by light and confocal laser
scanning microscopy. Care was taken to apply the same
brightness, sharpness, color saturation and contrast ad-
justments in the various pictures.
Huntingtin aggregation assays
Expression and purification of huntingtin
The expression vector pGEX-6P-1 containing exon-1 of
HTT and encoding 52 glutamine residues (HTTQ52)
was kindly provided by Zoya Ignatova, University of
Hamburg, and used to express recombinant HTT for ag-
gregation assays. HTTQ52 with N-terminal GST-tag
followed by a polyhistidine tag was expressed in E. coli
strain BL21 after induction with 400 μM IPTG at 24 °C
for 4 h. After harvesting by centrifugation, cells weredisrupted by enzymatic lysis and sonification. The first
purification step was carried out through Ni2+-chelating
chromatography on a Streamline Chelating resin
(Streamline Chelating, GE Healthcare Life Sciences).
Fractions containing the expression construct were fur-
ther purified in a second step via a glutathione sepharose
resin (Glutathione Sepharose 4FF, GE Healthcare Life
Sciences). The removal of glutathione was achieved by
dialysis overnight against buffer containing 50mM Tris/
HCl, 150 mM KCl, pH 8.5. Fractions of interest were ly-
ophilized and stored at − 20 °C until usage. The purity of
the samples was assessed by SDS-PAGE and mass spec-
trometry. Protein concentrations were determined using
UV absorption at 280 nm.
Synthesis of amyloid peptides
Synthesis and purification of Abeta (1–42) was performed
by solid-phase syntheses as described previously [68].
Structures and purities of the Abeta peptide were
confirmed by mass spectrometry. The lyophilized peptide
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overnight. The solvents were evaporated under a stream of
nitrogen and Abeta peptides were dissolved in 0.2M NaOH,
followed by buffer and finally titrated with 0.2M HCl.
ThT fluorescence kinetics assay
The thioflavin T (ThT) assay was carried out as de-
scribed previously [67]. The fibrillation process was in-
duced by cleavage of the GST and polyhistidine tag by
PreScission protease (GE Healthcare Life Sciences) and
monitored by ThT fluorescence (20 μM, Sigma-Aldrich)
at λex = 440 nm and λem = 490 nm in aggregation buffer
(50 mM Tris/HCl, 50 mM KCl, 4 mM MgCl2, pH 8.0) on
a FluoStar Optima plate reader (BMG Labtech, Orten-
berg, Germany). Signals were recorded at 30 °C under
continuous shaking (300 rpm). Data analysis was done
according to [38]. In brief, lag times (tlag) of the aggrega-
tion were determined by fitting the straight lines a to
the baseline of the lag phase and b as a tangent to the
steepest region of the growth phase curve. Tlag is defined
as the time point where the two lines a and b intersect.
To obtain the aggregation rate k, the growth phase was
fitted to the function: y = A + B*exp(−kx). Values were
obtained from 3 independent determinations and dis-
played as mean ± S.D.
Transmission electron microscopy and immunogold labelling
For immunogold staining the fibril samples (5 μl) were
fixed on formvar carbon-coated copper grids (Plano,
Wetzlar, Germany) with 2% (w/v) paraformaldehyde
(Merck, Darmstadt, Germany) in 0.1M HEPES buffer
(Thermo Fisher, Waltham, USA) for 20 min followed by
washing with distilled water. The sections were next in-
cubated for 30 min at RT with blocking solution (1% (w/
v) Bovine Serum Album (BSA, Sigma-Aldrich) with 0.1%
Tween-20 (Carl Roth, Karlsruhe, Germany) in 0.1M
HEPES buffer) to prevent unspecific binding. After
blocking, the grids were incubated overnight with the
primary antibodies directed against HTT (sheep poly-
clonal, S830, kindly provided by Gillian P. Bates,
London, UK; 1:500) and 6E10 (mouse monoclonal, rec-
ognizes Abeta (1–42), Merck; 1:250) diluted in blocking
solution. After 4 washes of 5 min with blocking solution
the grids were incubated for 90 min with secondary anti-
bodies coupled to colloidal gold: anti-sheep IgG 4 nm
gold (donkey polyclonal, Jackson ImmunoResearch,
Cambridgeshire, UK) and anti-mouse IgG 20 nm gold
(goat polyclonal, Abcam), 1:20 diluted in blocking solu-
tion. After three washing steps with distilled water the
grids were negative stained for 5 min with 2% (v/v) ur-
anyl acetate (SERVA Electrophoresis GmbH, Heidelberg,
Germany). Transmission electron microscopic images
were recorded using a Zeiss EM 912 Omega electron
microscope operating at 80 kV.Primary neuronal and astrocytic cultures
Primary neuronal and astroglial cultures were estab-
lished from APP-transgenic Tg2576 mice and wild type
littermates and grown under standard conditions [35].
Briefly, primary neuronal cell cultures were derived from
fetal mouse brain at gestation day 16. Astrocyte-rich
primary cell cultures were derived from brains of
newborn mice. Cells were grown in 24 well plates on
poly-L-lysine-coated coverslips and maintained in
DMEM-based medium at 37 °C in a humidified
atmosphere with 95% air/5% CO2. The purity of
primary cultures was verified by RT-PCR and by
immunocytochemistry against neuronal and astrocytic
markers (Additional file 1: Figure S2).RNA isolation and real time quantitative PCR
A real time quantitative polymerase chain reaction
(RT-qPCR) with RNA from primary neurons and astrocytes
derived from wild type and Tg2576 mouse brains, respect-
ively, was performed to analyze cell type-specific HTT ex-
pression. RNA of cultivated wild type and Tg2576 neurons
and astrocytes was isolated using the Trizol RNA isolation
protocol [10]. Quality and concentration of RNA was ana-
lyzed with the photometer NanoDrop 2000 at wavelengths
260 nm and 280 nm. Based on the results obtained from pri-
mer testing (Additional file 1: Figure S3a), two primer pairs
(#1 and #4) were chosen to analyze the HTT expression in
cultivated primary astrocytes and neurons. Primer pair #1 is
directed against a region spanning HTT exon 1 and 2,
whereas primer pair #4 recognizes a region located more
carboxy-terminally corresponding to the epitope of HTT
antibody used in this study. A one-step RT-qPCR was per-
formed to analyze expression of HTT. All working steps
were performed on ice and Qiagen RT-PCR Kit was used.
RNA of three wild type and three Tg2576 cell preparations
were diluted in RNase free water to obtain a 20 ng/μl solu-
tion. All diluted RNA samples were denatured in the Rotor
GeneTM 6000 Cycler at 70 °C for 5min to dissolve possible
secondary structures and were stored on ice until further
usage. Cyclophilin A (CycA) was used as reference gene.
Primers for CycA [81] and HTT (50 μM each) were diluted
in aqua dest. to obtain a concentration of 10 μM. Of all
samples 0.5 μl RNA were added to 9.5 μl of master mix and
the RT-qPCR was performed with a Rotor GeneTM 6000
Cycler according to Additional file 1: Table S1. Specificity of
PCR products was verified by electrophoresis and by ana-
lysis of the obtained CT values. A detailed analysis of thresh-
old cycle (CT) results obtained with RT-qPCR was
performed with the ΔΔCT method for relative quantifica-
tion. The linearity of results obtained was validated in a
standard curve (Additional file 1: Figure S3b) and PCR con-
trol experiments without RT and after DNAse treatment are
shown in Additional file 1: Figure S3c.
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To determine the cell type-specific expression of endogenous
HTT in primary neurons and astrocytes double immuno-
fluorescent labellings of HTT and cell type-specific markers
were performed as described for immunohistochemistry on
brain sections. Finally, coverslips were air-dried, embedded
in entellan/toluene on microscopic slides and stored at 4 °C
in the dark. Additionally, double labelling with neuron- and
astrocyte-specific antibodies was performed on neuronal and
astroglial primary cultures, to examine the identity and pur-
ity of the respective cell cultures.
Results
Expression of endogenous HTT in wild type mouse brain
First, the expression of endogenous HTT in C57BL/6 N
mouse brain was analyzed by immunohistochemistry.
HTT immunoreactivity was present at low levels
throughout the brain but was highly enriched in a num-
ber of morphologically clearly defined neuronal nuclei.
The identities of these nuclei brought out by HTT label-
ling were determined according to their morphology as
well as to their rostro-caudal and dorso-ventral position
using a mouse brain atlas [22].
At a high concentration of the primary antibody, a
wide-spread HTT immunoreactivity was detected through-
out the mouse brain. When diluting the HTT primary anti-
body from 1:500 to 1:4000, only neuronal populations with
highly abundant HTT expression were detected (Additional
file 1: Figure S1a). Applying a high HTT antibody dilution
to horizontal mouse brain sections, a significant number of
neuronal populations in caudal brain regions were still
strongly HTT immunoreactive while ubiquitous neuronal
staining was abolished (Fig. 1).
The screening of every 6th coronal section identified
HTT immunoreactive neurons at different coronal
levels. These populations include a distinct subpopula-
tion of striatal neurons, neurons in the basal forebrain
including medial septum (MS), vertical and horizontal
diagonal band (VDB/HDB), ventral pallidum (VP), olfac-
tory tubercle (Tu), nucleus basalis magnocellularis
(Nbm) as well as amygdala (Amy) (Fig. 2). At more cau-
dal coronal brain levels, significant HTT immunoreactiv-
ity was detected in Edinger-Westphal nucleus (EWN),
pedunculopontine tegmental nucleus (PPT), laterodorsal
tegmental nucleus (LDT), motor trigeminal nucleus
(Mo5), nucleus abducens (6), nucleus facialis (7) and the
perifacial zone (P7), the parvicellular medial vestibular
nucleus (MVePC), nucleus ambiguus (Amb), nucleus
vagus (10) and the hypoglossal nucleus (12) (Fig. 2).
Interestingly, EP867Y detected HTT immunoreactivity is
strongly enriched in cranial nerve nuclei and also signifi-
cantly present in basal forebrain and in a subset of striatal
neurons. In order to validate the identity of the HTT-positive
neuronal nuclei and subpopulations, respectively, doublelabellings with ChAT, Ucn-1, DARPP-32, a marker for
medium spiny neurons, and TH were performed. As a result,
almost all heavily stained HTT-positive nuclei were found to
be cholinergic which was evident by ChAT co-expression.
This demonstrates HTT expression by neurons of the re-
spective cranial nerve nuclei and by cholinergic neurons of
the basal forebrain (MS, VDB/HDB and Nbm) as well as
cholinergic interneurons of the striatum (Fig. 2). In contrast,
HTT immunoreactivity was absent from DARPP-32-positive
striatal medium spiny neurons and from TH-positive locus
coeruleus neurons neighboring the LDT (not shown). The
only non-cholinergic neuronal population showing high
HTT immunoreactivity in mouse brain was the Ucn-1-
positive neuronal subregion of EWN (Fig. 2). For a general
overview, the HTT immunoreactive neuronal populations
along the rostro-caudal extension of the brain and their attri-
bution to cranial nerve nuclei are summarized in Table 2.
Since this is the first detailed analysis of endogenous
HTT expression in mouse brain, we considered it im-
portant to validate our observations made in the C57BL/
6 N strain in brains of two other mouse lines (CD1 and
BALB/c). In the brains of these mouse lines very similar
HTT expression patterns were observed (not shown).
Also in Wistar rat (Fig. 3) and in hamster (Additional
file 1: Figure S4) as different rodent species there was an
enrichment of HTT immunoreactivity in cranial nerve
nuclei and in the cholinergic basal forebrain and caudate
putamen structures. A distinct difference to the HTT
immunoreactivity in mouse brain, however, was the la-
belling of neocortical neurons, in particular in layer III
pyramidal neurons, CA1 pyramidal neurons and dentate
gyrus granule neurons (Fig. 3; Additional file 1: Figure
S4), which was not depicted in mouse brain using the
same HTT antibody dilution. However, the cortical and
hippocampal neurons immunoreactive for HTT in rat
brain did not display a distinct cytoplasmic labelling typ-
ical for basal forebrain and cranial nerve nuclei, but ra-
ther a nuclear HTT localization. The presence of HTT
in neuronal nuclei is exemplarily shown for dentate
gyrus granule cells (Fig. 3). However, most neuronal
populations in basal forebrain and in cranial nerve nu-
clei displayed cytoplasmic/neuritic labelling (Fig. 3).
HTT expression and aggregation to Abeta plaques in
APP-transgenic Tg2576 mice
At sites of endogenous HTT expression, the formation of
cytotoxic HTT aggregates is likely when HTT variants with
expanded CAG repeats are expressed. However, in different
clinical conditions associated with pathogenic protein ag-
gregation in brain, the formation of protein co-aggregates
generated in cross-seeding events is reported.
In order to investigate potential protein cross seeding of
endogenous mouse HTT by Abeta aggregates, we analyzed
the HTT immunoreactivity in brains of 18-month-old
Fig. 1 Immunohistochemistry for huntingtin (HTT) on mouse horizontal brain sections (top, middle and right) and schematic presentation of
coronal cutting levels with high abundance of strongly HTT immunoreactive neurons. Note the enrichment of HTT immunoreactivity in caudal
brain structures. The anatomical templates used to illustrate cutting levels are shape and signal intensity averages from the Allen Mouse Brain
Connectivity Atlas [60]
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ally, the general HTTstaining pattern in Tg2576 mouse brain
reflected the labelling detected in wild type mice (not
shown). However, neocortical and hippocampal HTT immu-
noreactivity in aged Tg2576 mice appeared to be additionally
associated with amyloid plaque pathology. Therefore, a series
of double labellings of HTT with (i) ThS, (ii) the Abeta anti-
body 4G8 and (iii) the astrocyte marker GFAP were per-
formed and analyzed by confocal laser scanning microscopy
(Fig. 4a). These double immunofluorescent stainings demon-
strated a punctate HTT immunoreactivity in the near per-
iphery of fibrillary (ThS-positive) and Abeta-immunoreactive
extracellular plaques. This labelling pattern was consistently
detected irrespective of the brain region (hippocampus and
neocortex) and of plaque size. In addition, marked HTT im-
munoreactivity was detected in amyloid plaque-associated
reactive astrocytes (Fig. 4a) but not in microglial cells (not
shown). In brains of wild type mice neither punctate nor
astrocytic HTT immunoreactivity was observed (Fig. 4a).
In order to reveal whether HTT association with amyl-
oid plaques directly reflects its stimulated aggregation by
Abeta peptides, HTT aggregation assays in the absence or
presence of 1 μM Abeta (1–42) were performed. These
assays revealed stimulated HTT aggregation kinetics in
the presence of Abeta (Fig. 4b). While the HTT aggrega-
tion rate increased significantly in the presence of Abeta
peptides, no shortening of the lag phase was observed
(Fig. 4b). This indicates that Abeta peptides increase the
efficiency of the polymerization event while they do notaccelerate the nucleation process. The co-aggregation of
HTT with Abeta in fibrils was also demonstrated by
transmission electron microscopy (Fig. 4c).
Next, we sought to investigate whether the accumula-
tion of endogenous HTT near Abeta plaques and its in-
duction in reactive astrocytes are age-dependent and
increase along with plaque load. Therefore, coronal
brain sections of APP-transgenic mice at the postnatal
age of 15, 18, 20, 24 and 32months, respectively, were
used for immunocytochemical triple labelling of HTT, fi-
brillary Abeta plaques (ThS) and reactive astrocytes
(GFAP). We observed an age-dependent increase in hip-
pocampal HTT immunoreactivity, which was paralleled
by increases in plaque load and GFAP immunoreactivity
(Fig. 5). In negative control experiments without primary
antibodies, no labelling for HTT and GFAP was generated
(not shown). Additionally, in wild type mice no ThS-positive
deposits were detected and HTT and GFAP labellings were
comparable to young Tg2576 mice (Fig. 5).
The presence of astrocytic HTT immunoreactivity in
hippocampus of Tg2576 mice is particularly interesting
and may result from astrocytic HTT expression and/or
uptake of HTT released from neurons. In order to investi-
gate the capability of astrocytes to express HTT, Htt
mRNA and HTT protein expression were analyzed by
RT-qPCR and by immunocytochemistry in primary mouse
neuronal and astrocytic cultures. The purity of neuronal
and astrocytic cultures was demonstrated by the detection
of the neuronal marker NeuN and the astrocytic marker
Fig. 2 Immunohistochemical detection of huntingtin (HTT) in mouse brain. HTT is highly enriched in cholinergic striatal neurons (CPu), cholinergic neurons
of the basal forebrain including medial septum (MS), vertical and horizontal diagonal band (VDB/HDB) and nucleus basalis magnocellularis (Nbm) as well as in
cholinergic neurons of the olfactory tubercle (Tu), ventral pallidum (VP), and amygdala (Amy). At more caudal coronal brain levels, distinct
HTT immunoreactivity present in cholinergic (oculomotor nerve nucleus; 3) and in urocortin-1 positive neurons of the Edinger-Westphal nucleus (EWN),
pedunculopontine tegmental nucleus (PPT), laterodorsal tegmental nucleus (LDT), motor trigeminal nucleus (Mo5), nucleus abducens (6), nucleus facialis (7)
and perifacial zone (P7), the parvicellular medial vestibular nucleus (MVePC), nucleus vagus (10), the hypoglossal nucleus (12) and nucleus ambiguus (Amb)
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(Additional file 1: Figure S2). These data clearly
show the absence of neurons in astrocytic cultures
and vice versa.The analysis of RT-qPCR products by gel electrophor-
esis demonstrated the expected product size and similar
HTT expression levels in primary neurons and astro-
cytes of both, wild type and Tg2576 origin (Fig. 6a). CT
Fig. 2 Immunohistochemical detection of huntingtin (HTT) in mouse brain. HTT is highly enriched in cholinergic striatal neurons (CPu), cholinergic neurons
of the basal forebrain including medial septum (MS), vertical and horizontal diagonal band (VDB/HDB) and nucleus basalis magnocellularis (Nbm) as well as in
cholinergic neurons of the olfactory tubercle (Tu), ventral pallidum (VP), and amygdala (Amy). At more caudal coronal brain levels, distinct
HTT immunoreactivity present in cholinergic (oculomotor nerve nucleus; 3) and in urocortin-1 positive neurons of the Edinger-Westphal nucleus (EWN),
pedunculopontine tegmental nucleus (PPT), laterodorsal tegmental nucleus (LDT), motor trigeminal nucleus (Mo5), nucleus abducens (6), nucleus facialis (7)
and perifacial zone (P7), the parvicellular medial vestibular nucleus (MVePC), nucleus vagus (10), the hypoglossal nucleus (12) and nucleus ambiguus (Amb)
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mer pair were calculated and are shown in Table 3 with
the corresponding ΔCT value. The calculated ΔCT values
were further taken to perform relative quantification bycomparing the values among each other, obtaining ΔΔCT.
Subsequently, based on ΔΔCT values, the factor of differ-
ence between the two investigated samples was calculated
(Table 4). The relative quantification revealed that both
Fig. 2 Immunohistochemical detection of huntingtin (HTT) in mouse brain. HTT is highly enriched in cholinergic striatal neurons (CPu), cholinergic neurons
of the basal forebrain including medial septum (MS), vertical and horizontal diagonal band (VDB/HDB) and nucleus basalis magnocellularis (Nbm) as well as in
cholinergic neurons of the olfactory tubercle (Tu), ventral pallidum (VP), and amygdala (Amy). At more caudal coronal brain levels, distinct
HTT immunoreactivity present in cholinergic (oculomotor nerve nucleus; 3) and in urocortin-1 positive neurons of the Edinger-Westphal nucleus (EWN),
pedunculopontine tegmental nucleus (PPT), laterodorsal tegmental nucleus (LDT), motor trigeminal nucleus (Mo5), nucleus abducens (6), nucleus facialis (7)
and perifacial zone (P7), the parvicellular medial vestibular nucleus (MVePC), nucleus vagus (10), the hypoglossal nucleus (12) and nucleus ambiguus (Amb)
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levels with small fluctuations. In conclusion, by means of
Htt RT-qPCR we were able to validate that primary astro-
cytes of wild type and Tg2576 background do express Htt
mRNA in addition to primary neurons.
The data on Htt mRNA expression are supported by im-
munocytochemical labelling of HTT in mouse primary neu-
rons and astrocytes demonstrating neuronal and astrocytic
HTT protein expression (Fig. 6b). Interestingly, primary as-
trocytes from wild type mice expressed Htt mRNA and
HTT protein whereas in brain of adult mice astrocytic
HTT immunoreactivity was only observed in transgenic
mice and associated with amyloid pathology (Fig. 4).
Discussion
Expression of endogenous HTT in mouse brain
In HD, the number of CAG repeats of the HTT gene de-
termines the age of disease onset in a fully dominantfashion [47]. When assessing the neuronal populations
affected by pathogenic HTT protein aggregation, it is
very likely that neurons with abundant HTT expression
are more affected than neurons expressing low levels of
HTT or no HTT at all. Thus, the defined cellular HTT
expression levels might be decisive for the neuron
type-specific pathology. From that point of view it is sur-
prising that no detailed analyses on the neuron
type-specific endogenous HTT expression patterns in
brains of frequently used experimental animal species
exist. There is only an early report showing HTT immu-
noreactivity in the cytoplasm of neurons in rat neocortex
and in human cerebellar Purkinje and neocortical neu-
rons as well as neurons of caudate nucleus [17].
Therefore, we here comprehensively analyzed the brain
region- and neuron type-specific expression of endogen-
ous HTT in brains of three mouse lines, Wistar rat and
hamster using a monoclonal rabbit antibody (EP867Y)
Table 2 Neuronal populations with highly abundant HTT expression
Bregma [mm] structure name Association with cranial nerve nuclei
+ 0.98 MS medial septum nucleus
CPu caudate putamen
VP/Tu ventral pallidum olfactory tubercle I Nervus olfactorius
VDB/HDB nucleus ventral limb diagonal band
−0.82 Amy amygdaloid area
Nbm Nucleus basalis magnocellularis
−3.64 EWN Edinger Westphal nucleus
3 oculomotor nerve nucleus III Nervus oculomotorius
−4.96 PPT pedunculopontine tegmental nucleus
LDT laterodorsal tegmental nucleus
−5.34 Mo5/PCRtA motor trigeminal nucleus parvicellular reticular nucleus
−5.80 6 abducens nucleus VI Nervus abducens
7/P7 facial nucleus/perifacial zone VII Nervus facialis
−6.24 MVePC medial vestibular nucleus parvocellular VIII Nervus vestibulocochlearis
−7.48 10 dorsal motor nucleus vagus X Nervus vagus
12 hypoglossal nucleus XII Nervus hypoglossus
Amb ambiguus nucleus
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antibody is validated by Western blot analysis of HTT
knock-out cells analyzed along with wild type cells (Prod-
uct information sheet: https://www.abcam.com/hunting-
tin-antibody-ep867y-ab45169.html). Furthermore, in the
transgenic BACHD HTT mouse model we demonstrate
much stronger EP867Y labelling than in wild type mouse
brain tissue (Additional file 1: Figure S1b). In addition, the
specificity of the EP867Y antibody was demonstrated in a
number of recent publications [32, 56, 75].
Interestingly, in the striatum of all mouse lines tested, as
well as in rat and hamster, strong HTT immunoreactivity
stood out in cholinergic interneurons that are spared in
HD [20]. In contrast, in DARPP-32-positive striatal
medium-spiny neurons, which are known to be affected in
HD [29], significant HTT-labelling with the high threshold
selected here was missing. However, also in human brain
large striatal neurons that are spared in HD express HTT
[64] and deficits in cholinergic markers such as acetyl-
cholinesterase and vesicular acetylcholine transporter
without accompanying cell loss have been reported in HD
affected subjects [1, 73].
We detected ubiquitous low level HTT immunoreac-
tivity throughout the brain but a highly selective enrich-
ment of HTT in cholinergic neurons of the basalforebrain and amygdala, and in particular in cholinergic
neurons of cranial nerve nuclei. In addition, prominent
HTT expression was revealed in Ucn-1-positive EWN
neurons and represented the only non-cholinergic neur-
onal population with abundant HTT expression identi-
fied in the present study. These observations indicate
that not only neurons in striatum, but also defined neur-
onal populations in midbrain and brain stem may be af-
fected by the pathogenic mechanisms resulting from
polyQ extension of the HTT protein in HD. Indeed, in
HD patients HTT protein inclusions were demonstrated
in cranial nerve nuclei III (oculomotor nerve), IV (troch-
lear nerve), V (trigeminal nerve), VI (abducens nerve),
VII (facial nerve), VIII (vestibulocochlear nerve), IX
(glossopharyngeal nerve), X (vagal nerve) and XII
(hypoglossal nerve) [63]. This is in good accordance
with our observation of prominent HTT expression
in mouse, rat and hamster brain and would explain
some clinical symptoms, (i.e. oculomotor and vestibu-
lar deficits) that cannot solely be attributed to degen-
eration of striatal neurons. Interestingly, HTT-rich
vestibular projection neurons predominantly terminate
on HTT-negative medium spiny neurons in dorsolat-
eral striatum [78], where significant neurodegenera-
tion in HD occurs. Thus, in addition to local HTT
Fig. 3 Immunohistochemical HTT labelling in coronal brain sections of Wistar rat. Note the high abundance of HTT immunoreactivity in medial
septum (MS), caudate putamen (CPu), vertical and horizontal diagonal band (VDB/HDB), nucleus basalis magnocellularis (Nbm), oculomotor nerve
nucleus (3), pedunculopontine tegmental nucleus (PPT), laterodorsal tegmental nucleus (LDT), nucleus abducens (6), nucleus facialis (7) and
perifacial zone (P7). In addition and in contrast to mouse brain, significant HTT immunoreactivity was detected in cortical pyramidal neurons (Cx),
and in cornu ammonis 1 (CA1) pyramidal and dentate gyrus (DG) granule neurons of the hippocampus
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atum via innervating fibers should be considered
based on the evidence presented here.
We would like to note that this pattern of HTT expres-
sion was not recapitulated by other HTT antibodies such
as 2B7 and 2166. One possible explanation for this is
HTT cleavage by different proteases to generate numerous
fragments [44, 57] and the adoption of different conform-
ational states of the HTT protein [65, 69]. The epitope of
the EP867Y antibody is within amino acids 550 and 650 of
HTT and corresponds to residues specific to the apopain(caspase-3) cleavage site [27, 87]. Thus, this antibody ap-
pears to be unique and will allow monitoring distinct
HTT expression related to cholinergic nuclei.
From the pattern of endogenous HTT expression in
mouse, rat and hamster brain, one would predict that
under conditions of pathogenic HTT expression the cor-
responding neuronal functions such as the reward system
(VP, CPu, Tu, PPT, Amy), memory processing and deci-
sion making (Amy), arousal and attention (PPT), gener-
ation of REM sleep (LDT), pupil constriction and eye
movement (EWN, oculomotor nerve nucleus, nucleus
Fig. 4 a Association of HTT with Abeta plaques and presence in reactive astrocytes in entorhinal cortex of an 18-month-old Tg2576 mouse. HTT
immunoreactivity was found to be present in Abeta plaque-associated glia-like structures (Tg2576 left row, arrows) and aggregate-like structures in the
periphery of ThS-positive Abeta plaques (Tg2576 left row, asterisk). This correlation can also be shown using the pan-Abeta-specific antibody 4G8
(Tg2576 middle row). Double fluorescence labelling of HTT and GFAP demonstrates the presence of HTT in reactive astrocytes (arrows) surrounding
Abeta plaques (Tg2576 right row, asterisk). No glial HTT immunoreactivity or aggregate-like structures were detected in age-matched wild type mouse
entorhinal cortex (wild type row). b Aggregation of 22.5 μM HTT (red dotted line) and its stimulation by addition of 1 μM Abeta (1–42) (yellow solid
line) monitored by ThT fluorescence. Note the typical aggregation curve for 1 μM Abeta (1–42) aggregation alone (green broken line). Statistical
analysis revealed an accelerated HTT aggregation rate (right diagram) without effects on the lag phase (middle diagram) after addition of small
amounts of Abeta (1–42). c Electron microscopic demonstration of the co-occurrence of HTT (4 nm gold particles) and Abeta (1–42) (20 nm gold
particles) after immunogold labelling of fibrils generated from 22.5 μM HTT in the presence of 1 μM Abeta (1–42)
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nucleus vagus) and general sensory and motor functions
(facial nucleus, Pr5, Mo5, PPT, MVePC, ambiguus nu-
cleus, hypoglossal nucleus) are affected. Indeed, the clin-
ical features of HD such as progressive motor dysfunction,
cognitive decline and psychiatric disturbance [86] couldbe – at least partially – related to dysfunction or death of
these neuronal populations. Typical motor dysfunctions in
HD include chorea, dystonia, progressive bradykinesia, ri-
gidity and incoordination. In addition, many patients have
substantial cognitive or behavioral disturbances before on-
set of diagnostic motor signs [54]. Interestingly, deep brain
Fig. 5 Triple fluorescent labelling of HTT (red), fibrillary Abeta aggregates (ThS, green) and reactive astrocytes (GFAP, blue) in hippocampus of Tg2576
mice and wild type control. ThS plaque labelling as well as HTT and GFAP immunoreactivity in Tg2576 mice increased in an age-dependent manner
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tural difficulties in PD subjects [3, 79]. In addition, a
significant cholinergic innervation of the striatum and
nucleus accumbens arises from brainstem LDT and
PPT nuclei [14]. Thus, when affected during HD
pathogenesis, dysfunction and/or degeneration of
these neurons may contribute to striatal cholinergic
deficits. Indeed, targeting the cholinergic system hasFig. 6 RT-qPCR and immunocytochemistry for HTT expression in mouse prim
products obtained with Htt primer pair #1 at the calculated product size of 15
wild type (wt) and three Tg2576 (tg) mice. Note the similar expression levels f
of Htt-specific PCR product was normalized to the expression of the housekee
reveals the presence of HTT protein (green fluorescence) in primary neurons (
identified by NeuN, HuC/D labelling (red fluorescence) and astrocytes were mbeen proposed as novel HD therapy [18] and may
compensate deficits in numerous cholinergic nerve
nuclei with high HTT expression levels. This may
also apply to the hypoglossal nerve nucleus which
provides innervation of extrinsic and intrinsic muscles
of the tongue and, therefore, accounts for the prom-
inent dysphagia and disturbance of speech in HD pa-
tients [48, 53, 62].ary neuronal and astrocytic cultures. a In the upper lane the RT-qPCR
2 bp are shown for primary neurons and astrocytes derived from three
or Htt mRNA in wt and tg neuronal and astrocytic cultures. The amount
ping gene Cyclophilin A (CycA) (lower lane). b Immunocytochemistry
left) and primary astrocytes (right) as indicated by arrows. Neurons were
arked by GFAP immunocytochemistry (red fluorescence)
Table 3 Calculated CT means for each sample and primer pair with corresponding ΔCT value
Sample CT mean (cyclophilin) CT mean (Htt #1) ΔCT (Htt #1) CT mean (Htt #4) ΔCT (Htt #4)
Neurons wt 13.53 16.30 2.7 16.75 3.22
Neurons tg 13.82 16.22 2.4 17.41 3.59
Astrocytes wt 11.98 14.88 2.90 15.80 3.82
Astrocytes tg 12.06 15.26 3.21 16.1 4.05
wt wild type, tg transgenic Tg2576
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Neurons with highly abundant HTT immunoreactivity dis-
played cytoplasmic localization of HTT. This is consistent
with biochemical and electron microscopic analyses which
demonstrated the presence of HTT in neuronal cytoplasm
and an association with vesicle membrane proteins [17]. In
the cytoplasm, full length HTT seems to be particularly
involved in intracellular transport processes and vesicle
trafficking, as it interacts with microtubules and clathrin-
coated vesicles [24, 36, 82]. In neurons with lower endogen-
ous HTT expression levels, we also observed faint immu-
noreactivity in the nucleus. This is in line with reported
co-immunoprecipitates with the carboxy-terminal binding
protein, known to be a transcriptional co-repressor in the
nucleus [43]. An amino-terminal HTT fragment, however,
has also been shown to interact with a variety of proteins
important for nuclear function, like p53 [77] and nuclear
receptor co-repressor protein [5].
Transgenic HD models
In several transgenic mouse models of HD, mutant HTT
is randomly inserted within the genome and its expression
is typically driven by neuron-specific promoters other
than the endogenous HTT promoter. Most of these mice
develop ubiquitinated nuclear HTT inclusions but do not
exhibit the full neuropathological phenotype of human
HD brains [83]. In particular, brain regions affected by
neuronal loss differ from that in HD and the effects on oli-
godendrocytes and astrocytes in the human brain are not
recapitulated in transgenic mice [83]. On the other hand,
in knock in mouse models of HD, transgene expression is
driven by the endogenous mouse HTT promoter and
should lead to pathology in brain regions identified by us
as highly HTT expressing. Interestingly, the manifestation
of HD-typical pathology including brain atrophy, striatal
neuronal loss, severe motor phenotype, weight loss andTable 4 Comparison of CT means with ΔΔCT method
Compared samples ΔΔCT (Htt #1)
Neurons wt – tg −0.387
Astrocytes wt – tg 0.30
Neurons wt – astrocytes wt 0.13
Neurons tg – astrocytes tg 0.81
wt wild type, tg transgenic Tg2576premature death depends on the expression of N-terminal
HTT fragments as present in the R6/2 model expressing
exon 1 of the HTT protein under the control of human
HTT promoter [8, 49]. Unfortunately, the more caudal
brain regions containing cholinergic cranial nerve nuclei
identified by us as strongly immunoreactive for endogen-
ous HTT were not included in the analyses. Thus, we
strongly recommend the analyses of these structures and
would predict the detection of pathological alterations like
HTT protein aggregates and astrogliosis in these clearly
defined nuclei.
Protein cross seeding
An important aspect of the present work was the ana-
lyses of a potential HTT protein cross seeding by Abeta
aggregates in brains of transgenic mice with amyloid
pathology. As the amyloid pathology in the Tg2576
mouse model used is restricted to neocortex and hippo-
campus, we focused on HTT aggregation in proximity to
amyloid plaques in these brain regions. We observed an
extracellular halo of HTT immunoreactivity around amyl-
oid plaques labelled with the Abeta-specific antibody 4G8
or by the fibril intercalating dye ThS, respectively. Such
protein cross seeding events are known to occur for pro-
teins affected by a particular disease, such as Abeta and
tau proteins in AD [28], but also for proteins from differ-
ent clinical entities such as Abeta and α-synuclein proteins
affected in AD and PD [23, 46, 52, 55, 80], respectively.
We here demonstrate for the first time that also the en-
dogenous HTT proteins can cross-seed with Abeta aggre-
gates. This process has a clear age-related component and
Abeta plaque-associated HTT immunoreactivity in hippo-
campus increases with plaque load. Since Abeta plaques
also contain non-Abeta peptides that could be responsible
for HTT recruitment, we directly tested the aggregation of
HTT by Abeta (1-42) in ThT aggregation assays. WeFactor ΔΔCT (Htt #4) Factor
1.30 0.37 0.78
0.81 0.23 0.85
0.92 0.6 0.66
0.57 0.46 0.73
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the polymerization event but have no effect on the nucle-
ation process. The nucleation of polyQ HTT was reported
to underlie a different mechanism than nucleation of
other amyloid peptides [38]. PolyQ fibrils of HTT do not
reveal a typical β-sheet structure but rather assemble into
α-helical structures and oligomers which interfere with
polyQ sequences and facilitate the formation of amyloid
nuclei [58]. A similar effect could occur in the presence of
Abeta peptides generating conditions that favor β-sheet
structure and thus result in higher aggregation rates [74].
The biological significance and pathogenic potential of
these co-aggregates is not yet clear but they might repre-
sent novel therapeutic targets. It has been recently shown
in an AD mouse model that targeting one pathogenic pro-
tein by passive immunization also attenuates the depos-
ition of other pathogenic protein aggregates, most likely
by a mechanism involving activation of the complement
system and microglia [13].
Currently, no data are available on cross seeding of
HTT to Abeta plaques in AD brains. However, there are
several reports analyzing Abeta pathology in HD brains
[15, 40, 76]. Based on morphological amyloid and tau
staging in autopsy cases of HD, a rare co-existence of
HD and AD was reported, although initial neuropatho-
logical stages of AD were found to be present early in
HD patients [40]. On the other hand, in elderly HD sub-
jects with dementia, a high proportion of subjects dis-
played tau and amyloid pathology, suggesting that
co-occurrence of AD may contribute to cognitive decline
in elderly HD patients [15]. Moreover, a co-occurrence
of mixed proteinopathies involving oligomerization and
aggregation of Tau, α-synuclein and TDP-43 in late stage
HD was demonstrated [76], indicating common mecha-
nisms of pathological protein aggregation in different
neurodegenerative diseases.
HTT expression by astrocytes
In brain sections of Tg2576 mice used for the analyses
of HTT protein cross seeding to amyloid plaques we
surprisingly observed HTT immunoreactivity in reactive
astrocytes in proximity to Abeta plaques. This robust
astrocytic HTT immunoreactivity raises the question
whether HTT produced by and released from neurons is
taken up by astrocytes or whether it is expressed by
these glial cells. In order to address this issue, primary
neuronal and glial cell cultures from APP-transgenic
Tg2576 mice were established and analyzed for Htt
mRNA and protein expression. Both, primary neurons
and astrocytes were shown to express Htt mRNA and
protein. This is in agreement with immunohistochemical
labellings of brain slices and supportive of de novo syn-
thesis of HTT by astrocytes, rather than uptake of
neuron-derived HTT. However, in contrast to thelabelling of mouse brain sections, also astrocytes derived
from primary cultures of wild type mice expressed HTT
indicating that astrocytic HTT expression can generally
be induced under conditions of astrocytic activation and
independent of Abeta pathology. HTT immunoreactive
astrocytes were also detected in the caudate and puta-
men of HD subjects [72] and in a transgenic HTT
mouse model [71]. The intentional and specific mutant
HTT expression by astrocytes was demonstrated to
cause age-dependent neurological symptoms including
body weight loss, motor function deficits, increased sus-
ceptibility to glutamate-induced seizures and early death
[6, 7]. Moreover, the mutant HTT expression by cultured
primary astrocytes was shown to induce cell death of
co-cultured wild type neurons [71]. On the other hand, re-
duction of astrocytic mutant HTT expression slows dis-
ease progression in the BACHD conditional HD mouse
model and improves motor and psychiatric-like pheno-
types [89]. Thus, there is solid evidence to conclude that
astrocytic HTT expression contributes to neurodegenera-
tion in HD.
Conclusions
We demonstrate a selective enrichment of physiological,
endogenous HTT in cranial neve nuclei in mouse, rat
and hamster brain. Under clinical conditions of patho-
genic HTT variant expression, the functions of these
neuronal populations might be compromised. Indeed,
clinical symptoms of HD patients not related to dysfunc-
tion of striatal medium spiny neurons can be partly at-
tributed to pathogenesis in cranial nerve nuclei. We also
demonstrate for the first time an association of endogen-
ous HTT to amyloid plaques and the expression of HTT
by reactive astrocytes in a transgenic animal model of
AD. These data are in line with cross-disease mecha-
nisms of pathogenic protein co-aggregation present
under conditions of HD and AD.
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